Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Anxiety Disorders × nabiximols × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Pain 3 Neoplasms 3 Marijuana Abuse 3 Recurrence 1 Parasomnias 1 Pancreatic Neoplasms 1 Nausea 1 Glioblastoma 1 Chronic Pain 1 Cachexia 1 Brain Neoplasms 1 Anxiety Disorders 1 Anorexia 1 Advanced Malignant Solid Tumor 1

Interventions

Psilocybin 4 Psychotherapy 2 Fluoxetine 2 Cannabidiol 2 nabiximols 1 Yoga 1 Therapeutics 1 Sertraline 1 Selective Serotonin Reuptake Inhibitors 1 Pharmaceutical Preparations 1 Niacin 1 Neoadjuvant Therapy 1 N-Methyl-3,4-methylenedioxyamphetamine 1 Minocycline 1 Medical Marijuana 1 Ketamine 1 Injections 1 Hormones 1 Gemcitabine 1 Dronabinol 1 Donepezil 1 Citalopram 1 Cisplatin 1 Aromatherapy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03948074 2025-09-10

CAFCARS

British Columbia Cancer Agency

Phase 2 Completed

Anxiety Disorders, Nausea, Pain, Parasomnias

Data powered by HemOnc (CC BY 4.0) Colophon ⚡